These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

59 related items for PubMed ID: 7553066

  • 21. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase.
    Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT, Sirigu P.
    Cancer; 2005 Sep 15; 104(6):1246-54. PubMed ID: 16078259
    [Abstract] [Full Text] [Related]

  • 22. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
    Garbe C.
    Melanoma Res; 1993 Aug 15; 3(4):291-9. PubMed ID: 7693093
    [Abstract] [Full Text] [Related]

  • 23. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA, Kondadasula SV, Go MR, Lesinski GB, Ghosh-Berkebile R, Lehman A, Monk JP, Olencki T, Kendra K, Carson WE.
    Clin Cancer Res; 2006 Oct 01; 12(19):5850-8. PubMed ID: 17020993
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
    Franzke A, Buer J, Probst-Kepper M, Lindig C, Framzle M, Schrader AJ, Ganser A, Atzpodien J.
    Cancer Biother Radiopharm; 2001 Oct 01; 16(5):401-9. PubMed ID: 11776757
    [Abstract] [Full Text] [Related]

  • 27. HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2).
    Scheibenbogen C, Keilholz U, Mytilineos J, Suciu S, Manasterski M, Hunstein W.
    Melanoma Res; 1994 Jun 01; 4(3):191-4. PubMed ID: 7919965
    [Abstract] [Full Text] [Related]

  • 28. HLA associations in the antitumor response against malignant melanoma.
    Marincola FM, Shamamian P, Rivoltini L, Salgaller M, Cormier J, Restifo NP, Simonis TB, Venzon D, White DE, Parkinson DR.
    J Immunother Emphasis Tumor Immunol; 1995 Nov 01; 18(4):242-52. PubMed ID: 8680652
    [Abstract] [Full Text] [Related]

  • 29. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?
    Hoon DS, Okamoto T, Wang HJ, Elashoff R, Nizze AJ, Foshag LJ, Gammon G, Morton DL.
    J Clin Oncol; 1998 Apr 01; 16(4):1430-7. PubMed ID: 9552048
    [Abstract] [Full Text] [Related]

  • 30. Association of HLA phenotype with response to active specific immunotherapy of melanoma.
    Mitchell MS, Harel W, Groshen S.
    J Clin Oncol; 1992 Jul 01; 10(7):1158-64. PubMed ID: 1607920
    [Abstract] [Full Text] [Related]

  • 31. IL-2/TIL therapy: more effective for advanced melanoma.
    Oncology (Williston Park); 1989 Mar 01; 3(3):117. PubMed ID: 2641315
    [No Abstract] [Full Text] [Related]

  • 32. Association of Propionibacterium acnes endophthalmitis with HLA-DQw5.
    Davis JL, Winward KR, Lonardo EC, Nussenblatt RB, Meisler DM, Lee TD.
    Ocul Immunol Inflamm; 1996 Mar 01; 4(1):25-32. PubMed ID: 22827330
    [Abstract] [Full Text] [Related]

  • 33. Association of HLA-DOB1*0301 with malignant melanoma.
    Lee JE, Reveille JD, Platsoucas CD.
    J Immunother Emphasis Tumor Immunol; 1996 Sep 01; 19(5):381-5. PubMed ID: 8941878
    [No Abstract] [Full Text] [Related]

  • 34. Lack of effect of tumour infiltrating lymphocytes in patients with metastatic melanoma who failed to respond to interleukin 2.
    Dorval T, Mathiot C, Brandely M, Escande MC, Fridman WH, Pouillart P.
    Eur J Cancer; 1992 Sep 01; 28(2-3):615-6. PubMed ID: 1591084
    [No Abstract] [Full Text] [Related]

  • 35. HLA-DQ1 associated with reflex sympathetic dystrophy.
    van de Beek WJ, van Hilten JJ, Roep BO.
    Neurology; 2000 Aug 08; 55(3):457-8. PubMed ID: 10932297
    [No Abstract] [Full Text] [Related]

  • 36. Computing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical Characteristics.
    Dhall A, Patiyal S, Kaur H, Bhalla S, Arora C, Raghava GPS.
    Front Genet; 2020 Aug 08; 11():221. PubMed ID: 32273881
    [Abstract] [Full Text] [Related]

  • 37. Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.
    Bayless NL, Bluestone JA, Bucktrout S, Butterfield LH, Jaffee EM, Koch CA, Roep BO, Sharpe AH, Murphy WJ, Villani AC, Walunas TL.
    J Immunother Cancer; 2021 Sep 08; 9(9):. PubMed ID: 34479924
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.